History of worsening heart failure and outcomes with vericiguat in ambulatory HFrEF: an exploratory post hoc analysis of VICTOR
Open Access
- 28 August 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Abstract
No abstract availableFunding Information
- Bayer
- Merck Sharp & Dohme LLC
- Merck
This publication has 6 references indexed in Scilit:
- Blood Pressure, Safety and Clinical Efficacy of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR TrialEuropean Journal of Heart Failure, 2025
- Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2025
- Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR TrialEuropean Journal of Heart Failure, 2024
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2021
- Vericiguat in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2020